BioCentury | Oct 19, 2020
Finance

How Nimbus’ focus on internal pipeline could point to long-awaited exit

...that they have a combined $10 billion in capital...
BioCentury | Oct 6, 2020
Deals

Oct. 5 Quick Takes: BridgeBio reacquiring Eidos, Amgen KRAS data, after-hours tumbles for Iovance, Y-mAbs and more

...well as its previously announced $115 million private placement. The company has over $275 million in capital...
BioCentury | Apr 2, 2020
Finance

Billion-dollar funds from Arch, Flagship show VCs are open for business

...twentieth year, Flagship has founded more than 100 companies and has more than $4.4 billion in capital...
BioCentury | Feb 12, 2020
Finance

AurorA debuts to back early-stage European biotechs

...Rottapharm Biotech s.r.l. and specialty pharma Italfarmco S.p.A. Beyond providing the €10 million ($11 million) in capital...
BioCentury | Feb 8, 2020
Product Development

As coronavirus disrupts MNC operations in China, companies look to digital solutions

...22,112 cases -- are in Hubei province, where the virus was was first identified in capital...
BioCentury | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

...respectively. More than one-third of the pharma spinouts have already raised more than $100 million in capital...
BioCentury | Dec 6, 2019
Preclinical News

Dec. 5 Preclinical Quick Takes: Simpler synthesis of Merck’s HIV therapy; plus MRSA antibiotic, once-monthly oral contraceptive

...report , was 51%, and Codexis CEO John Nicols told BioCentury the process confers increases in capital...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...months of the year have not been kind to fund flows, with over $2.5 billion in capital...
BioCentury | May 15, 2019
Politics & Policy

DOJ death penalty opinion could hobble FDA oversight of countermeasures, street drugs

...drugs used to carry out death sentences. “FDA lacks jurisdiction over articles intended for use in capital...
BioCentury | Apr 26, 2019
Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

...of the University of California and Nextech Invest. The company has raised about $304 million in capital...
Items per page:
1 - 10 of 102
BioCentury | Oct 19, 2020
Finance

How Nimbus’ focus on internal pipeline could point to long-awaited exit

...that they have a combined $10 billion in capital...
BioCentury | Oct 6, 2020
Deals

Oct. 5 Quick Takes: BridgeBio reacquiring Eidos, Amgen KRAS data, after-hours tumbles for Iovance, Y-mAbs and more

...well as its previously announced $115 million private placement. The company has over $275 million in capital...
BioCentury | Apr 2, 2020
Finance

Billion-dollar funds from Arch, Flagship show VCs are open for business

...twentieth year, Flagship has founded more than 100 companies and has more than $4.4 billion in capital...
BioCentury | Feb 12, 2020
Finance

AurorA debuts to back early-stage European biotechs

...Rottapharm Biotech s.r.l. and specialty pharma Italfarmco S.p.A. Beyond providing the €10 million ($11 million) in capital...
BioCentury | Feb 8, 2020
Product Development

As coronavirus disrupts MNC operations in China, companies look to digital solutions

...22,112 cases -- are in Hubei province, where the virus was was first identified in capital...
BioCentury | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

...respectively. More than one-third of the pharma spinouts have already raised more than $100 million in capital...
BioCentury | Dec 6, 2019
Preclinical News

Dec. 5 Preclinical Quick Takes: Simpler synthesis of Merck’s HIV therapy; plus MRSA antibiotic, once-monthly oral contraceptive

...report , was 51%, and Codexis CEO John Nicols told BioCentury the process confers increases in capital...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...months of the year have not been kind to fund flows, with over $2.5 billion in capital...
BioCentury | May 15, 2019
Politics & Policy

DOJ death penalty opinion could hobble FDA oversight of countermeasures, street drugs

...drugs used to carry out death sentences. “FDA lacks jurisdiction over articles intended for use in capital...
BioCentury | Apr 26, 2019
Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

...of the University of California and Nextech Invest. The company has raised about $304 million in capital...
Items per page:
1 - 10 of 102